|
US6358915B1
(en)
*
|
1995-03-07 |
2002-03-19 |
George Washington University |
Methods for inhibiting metastasis
|
|
US5935860A
(en)
*
|
1995-03-07 |
1999-08-10 |
The George Washington University |
Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
|
|
US20060281681A1
(en)
|
1997-05-28 |
2006-12-14 |
Pilon Aprile L |
Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
|
|
US6255281B1
(en)
*
|
1997-05-28 |
2001-07-03 |
Claragen, Inc. And U.S. Government |
Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
|
|
US20020160948A1
(en)
*
|
1998-07-21 |
2002-10-31 |
Aprile Pilon |
Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
|
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
|
WO2001080872A1
(en)
*
|
2000-04-21 |
2001-11-01 |
George Washington University |
Method of binding integrin for treatment of cancer
|
|
EP1300159B1
(en)
*
|
2000-06-29 |
2007-10-10 |
Anthera Pharmaceuticals, Inc. |
Remedies for cancer
|
|
US20030114410A1
(en)
*
|
2000-08-08 |
2003-06-19 |
Technion Research And Development Foundation Ltd. |
Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
|
|
WO2003048341A2
(en)
*
|
2001-12-03 |
2003-06-12 |
Uab Research Foundation |
Cap-gly domain structure and uses thereof
|
|
AUPS282602A0
(en)
*
|
2002-06-07 |
2002-06-27 |
Garvan Institute Of Medical Research |
Method of inhibiting cell proliferation
|
|
US20050259483A1
(en)
*
|
2002-09-30 |
2005-11-24 |
Oncotherapy Science, Inc. |
Genes and polypeptides relating to prostate cancers
|
|
TW200413539A
(en)
*
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Genes and polypeptides relating to prostate cancers
|
|
WO2004046329A2
(en)
*
|
2002-11-14 |
2004-06-03 |
Pintex Pharmaceuticals, Inc. |
Levels of pin1 in normal and cancerous tissue
|
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
|
WO2005065069A2
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
|
US7070816B2
(en)
*
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
WO2005108683A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
|
US20070225242A1
(en)
*
|
2005-06-21 |
2007-09-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method and composition for treating and preventing tumor metastasis in vivo
|
|
EP1909777A2
(en)
*
|
2005-07-22 |
2008-04-16 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
IL184627A0
(en)
|
2007-07-15 |
2008-12-29 |
Technion Res & Dev Foundation |
Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
|
|
CN110372795A
(zh)
|
2007-08-02 |
2019-10-25 |
吉利德生物制剂公司 |
Lox和loxl2抑制剂及其应用
|
|
CN102292099A
(zh)
|
2008-05-13 |
2011-12-21 |
科拉森斯公司 |
在鼻炎治疗中使用的重组人cc10及其组合物
|
|
WO2010080769A2
(en)
|
2009-01-06 |
2010-07-15 |
Arresto Biosciences, Inc. |
Chemotherapeutic methods and compositions
|
|
RU2012110585A
(ru)
|
2009-08-21 |
2013-09-27 |
Джилид Байолоджикс, Инк. |
Каталичические домены лизилоксидазы и loxl2
|
|
EP2488205B1
(en)
|
2009-10-15 |
2016-09-21 |
Clarassance, Inc. |
Recombinant human cc10 protein for treatment of influenza
|
|
US9168285B2
(en)
|
2009-10-15 |
2015-10-27 |
Therabron Therapeutics, Inc. |
Recombinant human CC10 protein for treatment of influenza and ebola
|
|
RU2015108348A
(ru)
|
2010-02-04 |
2015-07-20 |
Джилид Байолоджикс, Инк. |
Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
|
|
EP2407554A1
(en)
|
2010-07-14 |
2012-01-18 |
Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron |
Methods and kits for the diagnosis of prostate cancer
|
|
EP2407555A1
(en)
|
2010-07-14 |
2012-01-18 |
Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada |
Methods and kits for the diagnosis of prostate cancer
|
|
ES2638089T3
(es)
*
|
2011-02-24 |
2017-10-18 |
Ventana Medical Systems, Inc. |
Presencia de reordenamientos del gen ERG y sobreexpresión de proteínas en NIP de bajo grado (NIP-BG) en biopsias de próstata
|